Cuál es el precio por Aerpio Pharmaceuticals, Inc. (ARPO)

Precio por Aerpio Pharmaceuticals, Inc. (ARPO) es de$2.20

Cuál es la capitalización de mercado por Aerpio Pharmaceuticals, Inc. (ARPO)

Capitalización de mercado por Aerpio Pharmaceuticals, Inc. (ARPO) es $40.53M

Aerpio Pharmaceuticals, Inc. (ARPO) Historial de Precios

Aerpio Pharmaceuticals Inc., a biopharmaceutical enterprise headquartered in Blue Ash, Ohio, currently employs 27 full-time staff. The company's core mission revolves around the research and development of therapeutic solutions for ocular diseases. Its product pipeline is spearheaded by AKB-9778, with two additional programs, AKB-4924 and ARP-1536, also under development. AKB-9778 is a small molecule designed to activate the Tie-2 pathway, intended for the treatment of diabetic retinopathy (DR). AKB-4924, another candidate, functions as a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha) and is being investigated for its potential in treating inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody that targets the same pathway as AKB-9778. It operates by attaching to the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP), thereby inhibiting its interaction with Tie-2. As of April 14, 2017, Aerpio had successfully concluded a Phase II clinical trial for AKB-9778, which involved 144 patients with diabetic macular edema. By the same date, a Phase Ia clinical trial for AKB-4924 in healthy volunteers had also been completed.

Año	Rendimiento
2021	51.82%
2020	142.74%
2019	-69.62%
2018	0.00%

Año

Rendimiento

2021

51.82%

2020

142.74%

2019

-69.62%

2018

0.00%

Empresa	Precio de la acción	Cambio 1a%	País
Vertex Pharmaceuticals Incorporated VRTX.US	$544.13	37.98%	US
Argenx SE ARGX.US	$1.04K	56.62%	NL
CSL Limited CSL.AX	$120.74	-14.98%	AU
Lonza Group AG LONN.SW	$761.87	7.04%	CH
Moderna, Inc. MRNA.US	$131.42	388.73%	US

Empresa

Precio de la acción

Cambio 1a%

País